{"url_path":"/sec/uncy/8-k/2026-07-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-074678-index.html","accession_number":"0001213900-26-074678","cik":"0001766140","ticker":"UNCY","issuer_name":"Unicycive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-074678-index.html","primary_entity_key":"0001766140","primary_entity_name":"Unicycive Therapeutics, Inc."},"word_count":131,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n \n\nThe\nCompany had an ending cash balance of approximately $61.4 million as of June 30, 2026.\n\n \n\nThe\npreliminary results for the second quarter ended June 30, 2026, have been prepared by and are the responsibility of management. Neither\nour independent registered public accounting firm, nor any other independent accountants, have audited, reviewed, compiled or performed\nany procedures with respect to the preliminary results, nor have they expressed any opinion or any other form of assurance with respect\nthereto.\n\n \n\n1\n\n \n\nSIGNATURE\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDated:\n        July 2, 2026\n\n  \n\n   \nUNICYCIVE\nTHERAPEUTICS, INC.\n\n \n \n\n \nBy:\n/s/\nShalabh Gupta\n\n \n \nShalabh\nGupta\n\n \n \nChief Executive Officer\n\n \n\n2"}